Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18657510 | IVALTINOSTAT COMBINATION THERAPY FOR TREATING PANCREATIC CANCER | May 2024 | October 2025 | Allow | 17 | 2 | 1 | No | No |
| 18513343 | HISTOLOGICAL SPECIMEN TREATMENT | November 2023 | January 2026 | Abandon | 26 | 3 | 0 | No | No |
| 18360627 | CRYOPRESERVING UNGULATE EMBRYOS | July 2023 | June 2025 | Abandon | 23 | 2 | 0 | No | No |
| 18220975 | METHODS OF RECOVERING OIL FROM MICROORGANISMS | July 2023 | February 2025 | Allow | 19 | 1 | 0 | No | No |
| 18338963 | FOLLICULAR FLUID METHOD | June 2023 | September 2025 | Abandon | 27 | 3 | 0 | No | No |
| 18062612 | COMPOSITIONS COMPRISING YEAST CELLS AND POLYPHENOLS AND THEIR USE | December 2022 | May 2025 | Abandon | 29 | 2 | 1 | No | No |
| 17758694 | TURKEY COLLAGEN HYDROLYSATES AND METHODS OF MAKING | July 2022 | September 2025 | Allow | 38 | 2 | 0 | No | No |
| 17785531 | Methods, Kits and Compositions for Diagnosing and Treating Renal Disease | June 2022 | October 2025 | Allow | 40 | 1 | 1 | No | No |
| 17780436 | BDELLOVIBRIO TREATMENT FOR AMYOTROPHIC LATERAL SCLEROSIS | May 2022 | April 2025 | Abandon | 34 | 0 | 1 | No | No |
| 17740126 | TREATING MYELIN DISEASES WITH OPTIMIZED CELL PREPARATIONS | May 2022 | August 2024 | Allow | 27 | 1 | 1 | Yes | No |
| 17769301 | PROBIOTIC COMPOSITIONS AND METHODS | April 2022 | December 2025 | Abandon | 44 | 2 | 1 | No | No |
| 17719084 | BACTERIOPHAGE COCKTAIL FOR CONTROL OF SALMONELLA AND ESCHERICHIA COLI | April 2022 | February 2025 | Abandon | 34 | 0 | 1 | No | No |
| 17765552 | Improved Methods for Purification of Sophorolipids | March 2022 | April 2025 | Allow | 37 | 1 | 1 | No | No |
| 17763005 | Treatment of Mitochondrial Deficits and Age-Related Diseases Using Blood Products | March 2022 | October 2025 | Abandon | 43 | 1 | 0 | No | No |
| 17685189 | CRYOPRESERVING UNGULATE EMBRYOS | March 2022 | August 2023 | Allow | 17 | 1 | 1 | Yes | No |
| 17673083 | METHODS OF ENHANCING THE POTENCY OF INCRETIN-BASED DRUGS IN SUBJECTS IN NEED THEREOF | February 2022 | September 2024 | Abandon | 31 | 3 | 1 | No | No |
| 17646143 | COMPOSITION FOR PREVENTION OR TREATMENT OF NEURODEVELOPMENTAL DISORDER, NEUROLOGIC DISEASES, OR PSYCHIATRIC DISEASES COMPRISING EXTRACELLULAR VESICLES DERIVED FROM MICROCOCCUS LUTEUS | December 2021 | February 2024 | Allow | 26 | 4 | 1 | Yes | No |
| 17616446 | METHOD FOR OPTIMIZING A FERMENTATION PROCESS | December 2021 | December 2025 | Abandon | 48 | 3 | 0 | No | No |
| 17455328 | Novel Lactobacillus Having Various Functions, and Use Thereof | November 2021 | August 2023 | Allow | 21 | 1 | 0 | Yes | No |
| 17478520 | ADAMTS13-CONTAINING COMPOSITIONS HAVING THROMBOLYTIC ACTIVITY | September 2021 | December 2023 | Abandon | 27 | 1 | 1 | No | No |
| 17431997 | NOVEL USES OF BOTULINUM NEUROTOXIN FOR THE TREATMENT OF TREMOR | August 2021 | December 2024 | Abandon | 40 | 5 | 1 | Yes | No |
| 17428788 | DEHYDRATED BIOFILM ASSEMBLIES AND METHODS FOR MANUFACTURING DEHYDRATED BIOFILM ASSEMBLIES | August 2021 | April 2024 | Abandon | 32 | 1 | 1 | No | No |
| 17392895 | DERMATOLOGICAL PREPARATIONS FOR MAINTAINING AND/OR RESTORING HEALTHY SKIN MICROBIOTA | August 2021 | August 2025 | Abandon | 49 | 4 | 0 | Yes | No |
| 17358333 | USE OF AKKERMANSIA FOR TREATING METABOLIC DISORDERS | June 2021 | December 2025 | Abandon | 53 | 3 | 0 | No | Yes |
| 17348038 | MACROMOLECULAR CLUSTERS OF CARDIAC STEM CELLS AND METHODS FOR MAKING AND USING THEM | June 2021 | December 2024 | Abandon | 42 | 3 | 0 | No | No |
| 17303946 | COMPOSITIONS AND METHODS COMPRISING BACTERIA FOR IMPROVING BEHAVIOR IN NEURODEVELOPMENTAL DISORDERS | June 2021 | June 2024 | Allow | 36 | 3 | 0 | Yes | No |
| 17298307 | MICROORGANISM FOR PRODUCING BIORETINOL AND METHOD OF PRODUCING BIORETINOL USING THE SAME | May 2021 | January 2025 | Abandon | 43 | 0 | 1 | No | No |
| 17332268 | FOLLICULAR FLUID | May 2021 | June 2023 | Abandon | 25 | 1 | 0 | No | No |
| 17296423 | Use of Megamonas funiformis in preventing and/or treating metabolic diseases | May 2021 | January 2025 | Allow | 44 | 2 | 0 | No | No |
| 17240542 | SECRETAGOGUES DERIVED FROM OXALOBACTER FORMIGENES | April 2021 | June 2024 | Abandon | 38 | 0 | 1 | No | No |
| 17288037 | METHOD OF EXTRACTING A PIGMENT FROM MICROALGAE | April 2021 | July 2024 | Abandon | 39 | 1 | 0 | No | No |
| 17287944 | METHOD FOR ANALYZING SAMPLES | April 2021 | June 2024 | Abandon | 38 | 1 | 0 | No | No |
| 17281849 | NOVEL USES OF BOTULINUM NEUROTOXIN FOR TREATING LIPOEDEMA | March 2021 | June 2024 | Abandon | 38 | 0 | 1 | No | No |
| 17279056 | HYDROLYSED PHOSPHOLIPID COMPOSITION AND METHOD OF MAKING THE SAME | March 2021 | December 2024 | Abandon | 45 | 1 | 1 | No | No |
| 17208107 | COMBINATION THERAPEUTICS USING TUMOR TREATING FIELDS (TTFIELDS) | March 2021 | July 2023 | Abandon | 28 | 1 | 0 | No | No |
| 17276555 | CLEANING COMPOSITIONS AND USES THEREOF | March 2021 | August 2024 | Abandon | 41 | 1 | 1 | No | No |
| 17276212 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING OBESITY OR SARCOPENIA, CONTAINING IF1 AS ACTIVE INGREDIENT | March 2021 | November 2024 | Allow | 44 | 2 | 0 | Yes | No |
| 17199484 | DEIMMUNIZED LYSOSTAPHIN AND METHODS OF USE | March 2021 | April 2024 | Allow | 37 | 1 | 0 | Yes | No |
| 17181482 | USE OF CELLS DERIVED FROM FIRST TRIMESTER UMBILICAL CORD TISSUE | February 2021 | June 2024 | Allow | 40 | 1 | 0 | Yes | No |
| 17170706 | Method for Engineering Three-Dimensional Synthetic Vascular Networks Through Mechanical Micromachining and Mutable Polymer Micromolding | February 2021 | February 2025 | Abandon | 48 | 3 | 1 | No | No |
| 17265238 | METHODS AND COMPOSITIONS RELATING TO INHIBITING CARDIOVASCULAR CALCIFICATION VIA ANNEXIN A1 | February 2021 | November 2024 | Abandon | 45 | 1 | 1 | No | No |
| 17164080 | IN VITRO METHOD, USE OF AN AGENT AND COLLECTION DEVICE FOR THE INHIBITION OF COAGULATION IN BLOOD | February 2021 | May 2023 | Abandon | 27 | 1 | 0 | No | No |
| 17264923 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISRODERS | February 2021 | February 2025 | Allow | 48 | 2 | 0 | No | No |
| 17258397 | SOLUBILIZATE WITH CURCUMIN AND AT LEAST THE CANNABINOID THC AS A FURTHER ACTIVE SUBSTANCE | January 2021 | September 2024 | Abandon | 44 | 1 | 1 | No | No |
| 15734327 | BLEOMYCIN FOR MIMICKING THE EFFECT OF IONIZING RADIATIONS ON T CELLS | December 2020 | April 2023 | Allow | 28 | 2 | 0 | Yes | No |
| 16952635 | COMPOSITION FOR PREVENTING, RELIEVING OR TREATING CLIMACTERIC DISORDERS COMPRISING LACTIC ACID BACTERIA AND PREBIOTICS | November 2020 | June 2023 | Allow | 31 | 1 | 0 | Yes | No |
| 17056451 | ELECTROPHORETIC BIOLOGICAL SAMPLE STAINING METHOD AND STAINING APPARATUS USING | November 2020 | February 2025 | Abandon | 51 | 2 | 1 | No | No |
| 17081844 | METHOD AND AN APPARATUS FOR TREATING PLANT BASED RAW MATERIAL WITH AN ENZYMATIC HYDROLYSIS | October 2020 | May 2024 | Allow | 42 | 1 | 0 | Yes | No |
| 17047851 | COMPOUNDS AND METHODS FOR THE IMMOBILIZATION OF MYOSTATIN-INHIBITORS ON THE EXTRACELLULAR MATRIX BY TRANSGLUTAMINASE | October 2020 | November 2025 | Allow | 60 | 3 | 1 | No | No |
| 16980189 | HIGH DENSITY 3D HEPATOCYTE SPHEROID PLATFORM FOR DRUG ADME STUDIES | September 2020 | May 2025 | Abandon | 56 | 3 | 0 | No | No |
| 16995405 | HUMAN MICROPHYSIOLOGICAL CELL SYSTEM FOR LIVER DISEASE | August 2020 | October 2025 | Abandon | 60 | 4 | 1 | No | No |
| 16991502 | CHROMOGENIC MEDIUM FOR THE DETECTION AND IDENTIFICATION OF VANCOMYCIN RESISTANT ENTEROCOCCI AND METHOD THEREFOR | August 2020 | December 2022 | Allow | 28 | 0 | 0 | Yes | No |
| 16989718 | METHODS OF RECOVERING OIL FROM MICROORGANISMS | August 2020 | June 2023 | Allow | 34 | 2 | 0 | Yes | No |
| 16935837 | PROBIOTIC THERAPIES FOR TREATING RETT SYNDROME | July 2020 | September 2023 | Allow | 38 | 2 | 0 | Yes | No |
| 16915851 | METHOD FOR CLASSIFYING/COUNTING LEUKOCYTES, REAGENT KIT FOR CLASSIFYING LEUKOCYTES, AND REAGENT FOR CLASSIFYING LEUKOCYTES | June 2020 | April 2024 | Allow | 46 | 3 | 1 | Yes | No |
| 16954659 | PROBIOTICS FOR COGNITIVE AND MENTAL HEALTH | June 2020 | March 2024 | Abandon | 45 | 1 | 1 | No | No |
| 16852236 | METHODS FOR THE ISOLATION OF MICROBES WITH ENHANCED PERSISTANCE AND COMPOSITIONS WITH SUCH MICROBES | April 2020 | April 2023 | Allow | 36 | 2 | 1 | Yes | No |
| 16832010 | INCORPORATION OF PHOSPHATIDYLCHOLINE IN A MEDIA COMPOSITION | March 2020 | October 2023 | Abandon | 43 | 5 | 0 | No | No |
| 16648175 | Composition for Increasing Muscle Mass | March 2020 | March 2024 | Abandon | 48 | 5 | 0 | Yes | No |
| 16816403 | CLEANING COMPOSITIONS COMPRISING ENZYMES | March 2020 | December 2023 | Abandon | 45 | 4 | 1 | No | Yes |
| 16644769 | METHOD FOR DIAGNOSING PANCREATIC CANCER USING METHIONYL-TRNA SYNTHETASE, AND PANCREATIC CANCER DIAGNOSTIC KIT USING SAME | March 2020 | June 2024 | Abandon | 51 | 2 | 1 | No | No |
| 16641622 | INACTIVATED BACILLUS COAGULANTS AND USES THEREOF FOR REDUCING STRESS | February 2020 | April 2025 | Abandon | 60 | 4 | 0 | No | Yes |
| 16799369 | HISTOLOGICAL SPECIMEN TREATMENT | February 2020 | December 2023 | Allow | 45 | 5 | 1 | Yes | No |
| 16637283 | A METHOD FOR REMEDIATION OF CONTAMINATED LANDS | February 2020 | April 2021 | Allow | 14 | 5 | 0 | Yes | No |
| 16635012 | BIOMARKERS IN EX VIVO LUNG PERFUSION (EVLP) PERFUSATE | January 2020 | April 2025 | Abandon | 60 | 5 | 1 | No | No |
| 16743304 | Methods for Localized Modification of Tissue Products | January 2020 | August 2022 | Abandon | 31 | 1 | 0 | No | No |
| 16724333 | IN VITRO BILIARY EXCRETION ASSAY | December 2019 | August 2022 | Abandon | 32 | 1 | 0 | No | No |
| 16722541 | METHOD OF CELL CULTURE | December 2019 | September 2025 | Allow | 60 | 7 | 0 | No | No |
| 16723723 | USE OF AKKERMANSIA FOR TREATING METABOLIC DISORDERS | December 2019 | January 2021 | Abandon | 13 | 0 | 0 | No | No |
| 16723720 | USE OF AKKERMANSIA FOR TREATING METABOLIC DISORDERS | December 2019 | January 2021 | Abandon | 13 | 0 | 0 | No | No |
| 16709232 | USE OF AKKERMANSIA FOR TREATING METABOLIC DISORDERS | December 2019 | September 2020 | Abandon | 10 | 1 | 0 | No | No |
| 16709238 | USE OF AKKERMANSIA FOR TREATING METABOLIC DISORDERS | December 2019 | August 2020 | Abandon | 8 | 1 | 0 | No | No |
| 16698116 | METHOD, COMPOSITION, AND ARTICLE OF MANUFACTURE FOR PROVIDING ALPHA-1 ANTITRYPSIN | November 2019 | November 2023 | Abandon | 48 | 3 | 0 | No | No |
| 16690238 | MULTI-COMPONENT DETERGENTS OR CLEANSERS CONTAINING A QUINONE OXIDOREDUCTASE | November 2019 | January 2023 | Abandon | 38 | 2 | 1 | No | No |
| 16496971 | URINE FLOW CYTOMETRY AS BIOMARKER OF RENAL DISEASES | September 2019 | February 2023 | Abandon | 41 | 0 | 1 | No | No |
| 16496719 | A NOVEL PROBIOTIC LACTOBACILLUS CASEI STRAIN AND ITS USES | September 2019 | July 2023 | Allow | 45 | 4 | 1 | Yes | No |
| 16530502 | CARBON MONOXIDE AND CARBON DIOXIDE BIOCONVERSION PROCESS | August 2019 | July 2023 | Allow | 48 | 2 | 1 | Yes | No |
| 16530481 | CARBON DIOXIDE BIOCONVERSION PROCESS | August 2019 | June 2023 | Allow | 46 | 2 | 1 | Yes | No |
| 16520366 | COMPOSITE PROBIOTICS AND USE THEREOF | July 2019 | May 2022 | Allow | 34 | 2 | 1 | Yes | No |
| 16478001 | METHODS FOR IMPROVING FERTILITY IN ARTIFICIAL INSEMINATION | July 2019 | June 2023 | Abandon | 47 | 2 | 1 | No | No |
| 16456972 | IN-VITRO METHODS FOR CLASSIFYING DRUGS ACCORDING TO THEIR POTENTIAL TO CAUSE LIVER CELL INJURY | June 2019 | February 2023 | Abandon | 44 | 1 | 1 | No | No |
| 16474803 | A BLOOD COAGULATION FACTOR REPLACEMENT PRODUCT FOR USE IN THE TREATMENT OR PROPHYLAXIS OF BLEEDINGS | June 2019 | May 2023 | Allow | 46 | 2 | 1 | Yes | No |
| 16465320 | METHODS OF ENHANCING THE POTENCY OF INCRETIN-BASED DRUGS IN SUBJECTS IN NEED THEREOF | May 2019 | November 2021 | Allow | 30 | 2 | 1 | Yes | No |
| 16422311 | METHODS FOR TREATING AUTISM SPECTRUM DISORDER AND ASSOCIATED SYMPTOMS | May 2019 | August 2022 | Abandon | 39 | 2 | 1 | Yes | No |
| 16421068 | PHARMACEUTICAL COMPOSITIONS OF LIPASE-CONTAINING PRODUCTS, IN PARTICULAR OF PANCREATIN | May 2019 | January 2022 | Abandon | 32 | 1 | 0 | No | No |
| 16349033 | Competition Test of an Enzyme Substrate with Internal Compensation for Enzyme Activity | May 2019 | September 2022 | Abandon | 41 | 2 | 1 | No | No |
| 16348542 | THERAPEUTIC AGENT FOR CEREBRAL INFARCTION | May 2019 | October 2022 | Abandon | 41 | 2 | 1 | No | No |
| 16348252 | AUXOTROPHIC SELECTION SYSTEM | May 2019 | July 2023 | Abandon | 51 | 3 | 1 | No | No |
| 16285088 | USE OF AKKERMANSIA FOR TREATING METABOLIC DISORDERS | May 2019 | January 2021 | Abandon | 22 | 0 | 1 | No | No |
| 16403095 | USE OF PURIFIED 2'-FUCOSYLLACTOSE, 3-FUCOSYLLACTOSE AND LACTODIFUCOTETRAOSE AS PREBIOTICS | May 2019 | May 2024 | Abandon | 60 | 4 | 1 | No | No |
| 16393684 | FATTY LIVER AND LIVER FIBROSIS EVALUATION SYSTEM BASED ON IMPEDANCE | April 2019 | March 2023 | Abandon | 47 | 1 | 1 | No | No |
| 16343696 | AGENT ACTING ON TRANSCELLULAR ION TRANSPORTER IN INTESTINAL TRACT, AGENT FOR ACTIVATING CHLORIDE CHANNEL, AGENT FOR PREVENTING OR TREATING RENAL DISEASE, OR AGENT FOR PROMOTING DEFECATION | April 2019 | April 2022 | Allow | 36 | 3 | 0 | Yes | No |
| 16384703 | PHARMACEUTICAL COMPOSITION CONTAINING DEOXYCHOLIC ACID | April 2019 | September 2023 | Abandon | 53 | 5 | 0 | No | No |
| 16379276 | METHODS OF REMOVING ALPHA-GALACTOSE | April 2019 | January 2022 | Abandon | 34 | 2 | 0 | No | No |
| 16377041 | METHOD FOR PREPARING CORNEAL TISSUE | April 2019 | May 2022 | Abandon | 37 | 3 | 0 | Yes | No |
| 16335852 | Process of Converting Carbon Dioxide Using Combination of Carbon Dioxide Mineralization Process and Metabolism of Sulfur-Oxidizing Microorganisms | March 2019 | August 2023 | Allow | 53 | 4 | 1 | Yes | No |
| 16334623 | A DETERGENT PRODUCT FOR COSMETIC USE | March 2019 | June 2021 | Allow | 27 | 2 | 0 | Yes | No |
| 16329483 | METHOD FOR CULTURING PHOTOSYNTHETIC MICROALGAE | February 2019 | June 2021 | Abandon | 28 | 1 | 0 | Yes | No |
| 16270415 | SYSTEM AND METHOD FOR SEQUESTERING SUBSTANCES IN BULK LIQUIDS | February 2019 | November 2020 | Allow | 21 | 0 | 0 | Yes | No |
| 16266653 | MICROORGANISMS INHIBITING THE FORMATION OF FOOT MALODOR | February 2019 | December 2021 | Abandon | 35 | 1 | 1 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner GOUGH, TIFFANY MAUREEN.
With a 3.8% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 4.2% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner GOUGH, TIFFANY MAUREEN works in Art Unit 1651 and has examined 463 patent applications in our dataset. With an allowance rate of 29.4%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 46 months.
Examiner GOUGH, TIFFANY MAUREEN's allowance rate of 29.4% places them in the 4% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by GOUGH, TIFFANY MAUREEN receive 2.79 office actions before reaching final disposition. This places the examiner in the 81% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.
The median time to disposition (half-life) for applications examined by GOUGH, TIFFANY MAUREEN is 46 months. This places the examiner in the 10% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +50.1% benefit to allowance rate for applications examined by GOUGH, TIFFANY MAUREEN. This interview benefit is in the 93% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 8.4% of applications are subsequently allowed. This success rate is in the 4% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 23.4% of cases where such amendments are filed. This entry rate is in the 31% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.
When applicants request a pre-appeal conference (PAC) with this examiner, 44.4% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 40% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.
This examiner withdraws rejections or reopens prosecution in 38.1% of appeals filed. This is in the 6% percentile among all examiners. Of these withdrawals, 68.8% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner rarely withdraws rejections during the appeal process compared to other examiners. If you file an appeal, be prepared to fully prosecute it to a PTAB decision. Per MPEP § 1207, the examiner will prepare an Examiner's Answer maintaining the rejections.
When applicants file petitions regarding this examiner's actions, 75.6% are granted (fully or in part). This grant rate is in the 81% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 1.9% of allowed cases (in the 74% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).
Quayle Actions: This examiner issues Ex Parte Quayle actions in 1.5% of allowed cases (in the 65% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.